Co-crystals as a new approach to multimodal analgesia and the treatment of pain

References

• Faculty of Pain Medicine. The Royal College of Anaesthetists. Core standards for pain management services in the UK; 2015 Available from: https://www.rcoa.ac.uk/system/files/FPM-CSPMS-UK2015.pdf. Accessed 1128, 2018.
   Google Scholar
• Mura P, Serra E, Marinangeli F, et al. Prospective study on prevalence, intensity, type, and therapy of acute pain in a second-level urban emergency department. J Pain Res. 2017;10:2781–2788. doi:10.2147/JPR.S13413329263692
   PubMed Web of Science ®Google Scholar
• Gregory J, McGowan L. An examination of the prevalence of acute pain for hospitalised adult patients: a systematic review. J Clin Nurs. 2016;25(5–6):583–598. doi:10.1111/jocn.2016.25.issue-5pt626778249
   PubMed Web of Science ®Google Scholar
• Fayaz A, Croft P, Langford RM, Donaldson LJ, Jones GT. Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies. BMJ Open. 2016;6(6):e010364. doi:10.1136/bmjopen-2015-010364
   PubMed Web of Science ®Google Scholar
• Leadley RM, Armstrong N, Lee YC, Allen A, Kleijnen J. Chronic diseases in the European Union: the prevalence and health cost implications of chronic pain. J Pain Palliat Care Pharmacother. 2012;26(4):310–325. doi:10.3109/15360288.2012.73693323216170
   PubMedGoogle Scholar
• Moore RA, Derry S, Aldington D, Wiffen PJ. Single dose oral analgesics for acute postoperative pain in adults - an overview of Cochrane reviews. Cochrane Database Syst Rev. 2015;(9):CD008659.26414123
   PubMed Web of Science ®Google Scholar
• Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists’ Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain. 2016;17(2):131–157. doi:10.1016/j.jpain.2015.12.00626827847
   PubMed Web of Science ®Google Scholar
• Sinatra R. Causes and consequences of inadequate management of acute pain. Pain Med. 2010;11(12):1859–1871. doi:10.1111/j.1526-4637.2010.00983.x21040438
   PubMed Web of Science ®Google Scholar
• Borsook D, Hargreaves R, Bountra C, Porreca F. Lost but making progress–where will new analgesic drugs come from? Sci Transl Med. 2014;6(249):249sr243. doi:10.1126/scitranslmed.3008320
   Web of Science ®Google Scholar
• Gan TJ. Poorly controlled postoperative pain: prevalence, consequences, and prevention. J Pain Res. 2017;10:2287–2298. doi:10.2147/JPR.S13413329026331
   PubMed Web of Science ®Google Scholar
• Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet. 2006;367(9522):1618–1625. doi:10.1016/S0140-6736(06)68700-X16698416
   PubMed Web of Science ®Google Scholar
• Meissner W, Coluzzi F, Fletcher D, et al. Improving the management of post-operative acute pain: priorities for change. Curr Med Res Opin. 2015;31(11):2131–2143. doi:10.1185/03007995.2015.109212226359332
   PubMed Web of Science ®Google Scholar
• International Association for the Study of Pain. Task force on multimodal pain treatment defines terms for chronic pain care; 2017 Available from: https://www.iasp-pain.org/PublicationsNews/NewsDetail.aspx?ItemNumber=6981. Accessed 1128, 2018.
   Google Scholar
• Raffa RB, Pergolizzi JV Jr., Tallarida RJ. The determination and application of fixed-dose analgesic combinations for treating multimodal pain. J Pain. 2010;11(8):701–709. doi:10.1016/j.jpain.2009.12.01020338825
   PubMed Web of Science ®Google Scholar
• O’Brien J, Pergolizzi JV, van der Laar M, et al. Fixed-dose combinations at the front line of multimodal pain management: perspective of the nurse-prescriber. Nurs Res Rev. 2013;3:9–22. doi:10.2147/NRR.S36876
   Google Scholar
• Elvir-Lazo OL, White PF. The role of multimodal analgesia in pain management after ambulatory surgery. Curr Opin Anesthesiol. 2010;23(6):697–703. doi:10.1097/ACO.0b013e32833fad0a
   PubMed Web of Science ®Google Scholar
• Dale R, Stacey B. Multimodal treatment of chronic pain. Med Clin North Am. 2016;100(1):55–64. doi:10.1016/j.mcna.2015.08.01226614719
   PubMed Web of Science ®Google Scholar
• Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005;48(21):6523–6543. doi:10.1021/jm049494r16220969
   PubMed Web of Science ®Google Scholar
• Dhillon S. Tramadol/paracetamol fixed-dose combination: a review of its use in the management of moderate to severe pain. Clin Drug Investig. 2010;30(10):711–738. doi:10.2165/11205830-000000000-00000
   PubMed Web of Science ®Google Scholar
• Thipparaboina R, Kumar D, Chavan RB, Shastri NR. Multidrug co-crystals: towards the development of effective therapeutic hybrids. Drug Discov Today. 2016;21(3):481–490. doi:10.1016/j.drudis.2016.02.00126869329
   PubMed Web of Science ®Google Scholar
• Gattrell W, Johnstone C, Patel S, Smith CS, Scheel A, Schindler M. Designed multiple ligands in metabolic disease research: from concept to platform. Drug Discov Today. 2013;18(15–16):692–696. doi:10.1016/j.drudis.2013.02.00623454344
   PubMed Web of Science ®Google Scholar
• Geldenhuys WJ, Youdim MB, Carroll RT, Van der Schyf CJ. The emergence of designed multiple ligands for neurodegenerative disorders. Prog Neurobiol. 2011;94(4):347–359. doi:10.1016/j.pneurobio.2011.04.01021536094
   PubMed Web of Science ®Google Scholar
• Duggirala NK, Perry ML, Almarsson O, Zaworotko MJ. Pharmaceutical cocrystals: along the path to improved medicines. Chem Commun (Camb). 2016;52(4):640–655. doi:10.1039/c5cc09289b26565650
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Reflection paper on the use of cocrystals of active substances in medicinal products; 2015 Available from: https://www.ema.europa.eu/documents/scientific-guideline/reflection-paper-use-cocrystals-active-substances-medicinal-products_en.pdf. Accessed 1128, 2018.
   Google Scholar
• Aitipamula S, Banerjee R, Bansal AK, et al. Polymorphs, salts, and cocrystals: what’s in a name? Cryst Growth Des. 2012;12(5):2147–2152. doi:10.1021/cg3002948
   Web of Science ®Google Scholar
• US Food and Drug Administration. Guidance for industry. Regulatory classification of pharmaceutical co-crystals; 2018 Available from: https://www.fda.gov/downloads/Drugs/Guidances/UCM281764.pdf. Accessed 1128, 2018.
   Google Scholar
• Lara-Ochoa F, Espinosa-Pérez G. Cocrystals definitions. Supramol Chem. 2007;19(8):553–557. doi:10.1080/10610270701501652
   Web of Science ®Google Scholar
• Sekhon BS. Drug-drug co-crystals. Daru. 2012;20(1):45. doi:10.1186/2008-2231-20-4523351300
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Guidance for industry. Regulatory classification of pharmaceutical co-crystals; 2013 Available from: https://www.fda.gov/downloads/Drugs/Guidances/UCM281764.pdf. Accessed 1210, 2017.
   Google Scholar
• Thakuria R, Delori A, Jones W, Lipert MP, Roy L, Rodriguez-Hornedo N. Pharmaceutical cocrystals and poorly soluble drugs. Int J Pharm. 2013;453(1):101–125. doi:10.1016/j.ijpharm.2012.10.04323207015
   PubMed Web of Science ®Google Scholar
• Shan N, Perry ML, Weyna DR, Zaworotko MJ. Impact of pharmaceutical cocrystals: the effects on drug pharmacokinetics. Expert Opin Drug Metab Toxicol. 2014;10(9):1255–1271. doi:10.1517/17425255.2014.86572325089559
   PubMed Web of Science ®Google Scholar
• Steed JW. The role of co-crystals in pharmaceutical design. Trends Pharmacol Sci. 2013;34(3):185–193. doi:10.1016/j.tips.2012.12.00323347591
   PubMed Web of Science ®Google Scholar
• Brittain HG. Pharmaceutical cocrystals: the coming wave of new drug substances. J Pharm Sci. 2013;102(2):311–317. doi:10.1002/jps.2340223192888
   PubMed Web of Science ®Google Scholar
• Bolla G, Nangia A. Pharmaceutical cocrystals: walking the talk. Chem Commun (Camb). 2016;52(54):8342–8360. doi:10.1039/c5cc09289b27278109
   PubMed Web of Science ®Google Scholar
• Astellas Pharma Inc. Approval of Suglat® tablets, a selective SGLT2 inhibitor for treatment of type 2 diabetes, in Japan; 2014 Available from: https://www.astellas.com/en/corporate/news/detail/approval-of-suglat-tablets-a-s.html. Accessed 1128, 2018.
   Google Scholar
• Ohkura T. Ipragliflozin: a novel sodium-glucose cotransporter 2 inhibitor developed in Japan. World J Diabetes. 2015;6(1):136–144. doi:10.4239/wjd.v6.i1.13625685284
   PubMed Web of Science ®Google Scholar
• Markham A. Ertugliflozin: first global approval. Drugs. 2018;78(4):513–519. doi:10.1007/s40265-018-0878-629476348
   PubMed Web of Science ®Google Scholar
• Mascitti V, Maurer TS, Robinson RP, et al. Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors. J Med Chem. 2011;54(8):2952–2960. doi:10.1021/jm200049r21449606
   PubMed Web of Science ®Google Scholar
• Frampton C Cocrystal clear solutions; 2010 Available from: https://www.soci.org/Chemistry-and-Industry/CnI-Data/2010/5/Cocrystal-clear-solutions. Accessed 1127, 2018.
   Google Scholar
• Imamura M, Nakanishi K, Shiraki R, Onda K, Sasuga D, Yuda M, inventors. Cocrystal of C-glycoside derivative and L-proline. Patent US8097592B2. 2007. doi:10.1094/PDIS-91-4-0467B
   Google Scholar
• Sherman B, inventor. Solid substances comprising valproic acid and sodium valproate. U.S. Patent 6077542. 2000.
   Google Scholar
• Holland J, Frampton C, Chorlton A, Gooding D, inventors. Aprepitant l-proline solvates - compositions and cocrystals. WO2013076659A1. 2012. doi:10.1094/PDIS-11-11-0999-PDN
   Google Scholar
• Viertelhaus M, Hafner A. Co-crystals and their advantages for APIs with challenging properties. Chim Oggi. 2015;33(5):23–26.
   Google Scholar
• Kuminek G, Cao F, de Oliveira Da Rocha AB, Cardoso SG, Rodríguez-Hornedo N. Cocrystals to facilitate delivery of poorly soluble compounds beyond-rule-of-5. Adv Drug Deliv Rev. 2016;101:143–166. doi:10.1016/j.addr.2016.04.02227137109
   PubMed Web of Science ®Google Scholar
• Cheney ML, Weyna DR, Shan N, Hanna M, Wojtas L, Zaworotko MJ. Coformer selection in pharmaceutical cocrystal development: a case study of a meloxicam aspirin cocrystal that exhibits enhanced solubility and pharmacokinetics. J Pharm Sci. 2011;100(6):2172–2181. doi:10.1002/jps.2243421491441
   PubMed Web of Science ®Google Scholar
• Collier R. Reducing the “pill burden”. CMAJ. 2012;184(2):E117–118. doi:10.1503/cmaj.109-407622231682
   PubMed Web of Science ®Google Scholar
• Maeno Y, Fukami T, Kawahata M, et al. Novel pharmaceutical cocrystal consisting of paracetamol and trimethylglycine, a new promising cocrystal former. Int J Pharm. 2014;473(1–2):179–186. doi:10.1016/j.ijpharm.2014.07.00825010838
   PubMed Web of Science ®Google Scholar
• Desai D, Wang J, Wen H, Li X, Timmins P. Formulation design, challenges, and development considerations for fixed dose combination (FDC) of oral solid dosage forms. Pharm Dev Technol. 2013;18(6):1265–1276. doi:10.3109/10837450.2012.66069922339230
   PubMed Web of Science ®Google Scholar
• Da Silva CCP, de Melo CC, Souza MS, Diniz LF, Carneiro RL, Ellena J. 5-fluorocytosine/5-fluorouracil drug-drug cocrystal: a new development route based on mechanochemical synthesis. J Pharm Innov. 2018; 14:50–56.
   Web of Science ®Google Scholar
• Feng L, Karpinski P, Sutton P, et al. LCZ696: a dual-acting sodium supramolecular complex. Tetrahedron Lett. 2012;53(3):275–276. doi:10.1016/j.tetlet.2011.11.029
   Web of Science ®Google Scholar
• Novartis Pharmaceuticals Corporation. Entresto prescribing information; 2017 Available from: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/entresto.pdf. Accessed 1128, 2018.
   Google Scholar
• European Medicines Agency. Entresto assessment report; 2015 Available from: https://www.ema.europa.eu/documents/assessment-report/entresto-epar-public-assessment-report_en.pdf. Accessed 1128, 2018.
   Google Scholar
• Novartis. Novartis’ new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril/valsartan); 2015 Available from: http://www.multivu.com/players/English/7488651-novartis-fda-approval-entresto/. Accessed 1128, 2018.
   Google Scholar
• Novartis Europharm Limited. Entresto summary of product characteristics; 2017 Available from: https://www.ema.europa.eu/documents/product-information/entresto-epar-product-information_en.pdf. Accessed 1128, 2018.
   Google Scholar
• Polomano RC, Fillman M, Giordano NA, Vallerand AH, Nicely KL, Jungquist CR. Multimodal analgesia for acute postoperative and trauma-related pain. Am J Nurs. 2017;117(3 Suppl 1):S12–26. doi:10.1097/01.NAJ.0000526748.61302.b628212146
   PubMedGoogle Scholar
• Zukowski M, Kotfis K. The use of opioid adjuvants in perioperative multimodal analgesia. Anaesthesiol Intensive Ther. 2012;44(1):42–46.23801513
   PubMedGoogle Scholar
• Maxwell C, Nicoara A. New developments in the treatment of acute pain after thoracic surgery. Curr Opin Anaesthesiol. 2014;27(1):6–11. doi:10.1097/ACO.000000000000002924296973
   PubMed Web of Science ®Google Scholar
• Varrassi G, Hanna M, Macheras G, et al. Multimodal analgesia in moderate-to-severe pain: a role for a new fixed combination of dexketoprofen and tramadol. Curr Med Res Opin. 2017;33(6):1165–1173. doi:10.1080/03007995.2017.130190328326850
   PubMed Web of Science ®Google Scholar
• Almansa C, Mercè R, Tesson N, Farran J, Tomàs J, Plata-Salamán CR. Co-crystal of tramadol hydrochloride–celecoxib (ctc): a novel API–API co-crystal for the treatment of pain. Cryst Growth Des. 2017;17(4):1884–1892. doi:10.1021/acs.cgd.6b01848
   Web of Science ®Google Scholar
• Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879–923. doi:10.2165/00003088-200443130-0000415509185
   PubMed Web of Science ®Google Scholar
• Penning TD, Talley JJ, Bertenshaw SR, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3- (trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib). J Med Chem. 1997;40(9):1347–1365. doi:10.1021/jm960803q9135032
   PubMed Web of Science ®Google Scholar
• McCormack PL. Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Drugs. 2011;71(18):2457–2489. doi:10.2165/11208240-000000000-0000022141388
   PubMed Web of Science ®Google Scholar
• Frampton JE, Keating GM. Celecoxib: a review of its use in the management of arthritis and acute pain. Drugs. 2007;67(16):2433–2474. doi:10.2165/00003495-200767160-0000817983259
   PubMed Web of Science ®Google Scholar
• Wadman M. The pain game. Nature. 2007;448(7152):400–401. doi:10.1038/nature0598417653159
   PubMed Web of Science ®Google Scholar
• Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016;375(26):2519–2529. doi:10.1056/NEJMoa161159327959716
   PubMed Web of Science ®Google Scholar
• Videla S, Lahjou M, Vaque A, et al. Single-dose pharmacokinetics of co-crystal of tramadol-celecoxib: results of a four-way randomized open-label phase I clinical trial in healthy subjects. Br J Clin Pharmacol. 2017;83(12):2718–2728. doi:10.1111/bcp.1339528810061
   PubMed Web of Science ®Google Scholar
• Merlos M, Portillo-Salido E, Brenchat A, et al. Administration of a co-crystal of tramadol and celecoxib in a 1:1 molecular ratio produces synergistic antinociceptive effects in a postoperative pain model in rats. Eur J Pharmacol. 2018;833:370–378. doi:10.1016/j.ejphar.2018.06.02229932927
   PubMed Web of Science ®Google Scholar
• Videla S, Lahjou M, Vaque A, et al. Pharmacokinetics of multiple doses of co-crystal of tramadol-celecoxib: findings from a 4-way randomized open-label Phase I clinical trial. Br J Clin Pharmacol. 2018;84(1):64–78. doi:10.1111/bcp.1342828888220
   PubMed Web of Science ®Google Scholar
• López-Cedrún J, Videla S, Burgueño M, et al. Co-crystal of tramadol-celecoxib in patients with moderate to severe acute post-surgical oral pain: a dose-finding, randomised, double-blind, placebo- and active-controlled, multicentre, phase II trial. Drug R D. 2018;18(2):137–148. doi:10.1007/s40268-018-0235-y
   Web of Science ®Google Scholar
• ClinicalTrials.gov. Efficacy and safety in a randomised acute pain study of MR308 (tramadol/celecoxib). (STARDOM1); 2018 Available from: https://clinicaltrials.gov/ct2/show/NCT02982161?term=MR308&rank=1. Accessed 1128, 2018.
   Google Scholar
• ClinicalTrials.gov. Efficacy and safety in a randomised acute pain study of MR308: STARDOM2. (STARDOM2); 2018 Available from: https://clinicaltrials.gov/ct2/show/NCT03062644?term=MR308&rank=2. Accessed 1128, 2018.
   Google Scholar
• ClinicalTrials.gov. Co-crystal E-58425 vs tramadol and celecoxib for moderate to severe acute pain after bunionectomy. Phase III clinical trial; 2018 Available from: https://clinicaltrials.gov/ct2/show/NCT03108482. Accessed 1128, 2018.
   Google Scholar